路透 - 视频

版本: US | UK | IN | CN | JP

video

Breakingviews TV: Gilead growth

2019年 7月 16日 星期二 - 03:25

The biotech giant is spending $5.1 billion on Belgian outfit Galapagos but won’t take control. That, says Robert Cyran, means Gilead can profit from the smaller drugmaker’s successes, while limiting the risk. It’s a smart move, as both Roche and Sanofi discovered.

▲ 隐藏详情

显示详情

The biotech giant is spending $5.1 billion on Belgian outfit Galapagos but won’t take control. That, says Robert Cyran, means Gilead can profit from the smaller drugmaker’s successes, while limiting the risk. It’s a smart move, as both Roche and Sanofi discovered.

分享到  - 微信
路透中文网

Breakingviews TV: Gilead growth

2019年 7月 16日 星期二 - 03:25